Reata Pharma (RETA) Adds Christy J. Oliger and Shamim Ruff to Board

April 15, 2021 6:48 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021.

“We are excited to welcome Ms. Ruff and Ms. Oliger to Reata’s board,” said Warren Huff, Reata’s Chief Executive Officer and President. “They join at a critical point in Reata’s development having just submitted our first New Drug Application for bardoxolone methyl (“bardoxolone”) for the treatment of chronic kidney disease caused by Alport syndrome. Both Ms. Ruff and Ms. Oliger bring a wealth of experience that will be invaluable in helping us achieve our mission to develop innovative therapies that change patients’ lives for the better.”

Ms. Oliger brings nearly 30 years of experience in the biopharmaceutical industry, serving in various commercial roles at Genentech, Inc. and Roche Holding AG from January 2000 until her retirement in July 2020, and at Schering-Plough Corporation from September 1992 until December 1999. Most recently, Ms. Oliger served as Senior Vice President, Oncology Business Unit Head, at Genentech, Inc. During her tenure at Genentech, Inc., Ms. Oliger held senior leadership roles across a variety of therapeutic areas, including oncology, neurology, rare diseases, respiratory, dermatology, and immunology in hospital and specialty settings. She currently serves on the board of directors of Karyopharm Therapeutics Inc., a publicly traded pharmaceutical company. Ms. Oliger received a B.A. in Economics from the University of California at Santa Barbara.

“I am pleased to be joining Reata’s Board of Directors at this pivotal moment,” said Ms. Oliger. “I look forward to working with Reata’s seasoned management team to prepare for the next stage in the Company’s growth and the commercial launch of bardoxolone in the United States and internationally, subject to regulatory review and approval.”

Ms. Ruff brings over 30 years of experience in the biopharmaceutical industry, serving in various regulatory roles. Ms. Ruff has served as Chief Regulatory Affairs Officer and Senior Vice President, Head of Quality Assurance, at Stoke Therapeutics, Inc. since December 2018. From January 2013 to May 2018, Ms. Ruff served in various roles at Sarepta Therapeutics, Inc., including as Chief Regulatory Officer and Senior Vice President, Quality, from December 2015 to May 2018. Prior to her time at Sarepta Therapeutics, Inc., Ms. Ruff served in increasing senior regulatory roles at Sanofi, Amgen Inc., Abbott Laboratories, and AstraZeneca PLC. Ms. Ruff holds a bachelor’s degree in Chemistry and Biology from the University of Leicester, UK, and a master’s degree in Analytical Chemistry from the University of Loughborough, UK. Additionally, she is a Chartered Chemist and Member of the Royal Society of Chemistry.

“I am delighted with the opportunity to join Reata’s Board of Directors,” said Ms. Ruff. “The results from the CARDINAL Phase 3 trial of bardoxolone in patients with chronic kidney disease caused by Alport syndrome as well as results from Part 2 of the MOXIe trial of omaveloxolone in patients with Friedreich’s ataxia highlight the potential of these novel therapies to treat patients affected by these deadly rare diseases. I’m thrilled with the opportunity to help advance these molecules through the next stages of development.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Board Changes, Corporate News, Management Comments